FIELD: chemistry; biochemistry.
SUBSTANCE: invention relates to biotechnology and is a tumour necrosis factor receptor 1 antagonist which is a TNFR1 domain antibody (dAb). The invention also pertains to a TNFR1 domain antibody (dAb) monomer which binds the tumour necrosis factor receptor 1, as well as to a ligand which contains such a monomer. The invention also relates to a method of inhibiting signal transmission through the TNFR1 receptor using said antagonists. The invention also discloses nucleic acid which codes said antagonist, a vector containing said nucleic acid, a host cell containing said vector, a pharmaceutical composition containing said antagonist or said dAb monomer.
EFFECT: invention can be effective in treating inflammatory diseases (for example chronic inflammatory diseases).
57 cl, 99 dwg, 14 tbl, 20 ex
| Title | Year | Author | Number |
|---|---|---|---|
| CHIMERIC PROTEIN COMPOSED OF NGF ANTAGONIST DOMAIN AND TNFα ANTAGONIST DOMAIN | 2015 |
|
RU2678810C2 |
| ANTIBODIES SPECIFIC FOR LIGAND 1A, SIMILAR TO TUMOR NECROSIS FACTOR, AND THEIR COMPOSITIONS AND APPLICATION | 2014 |
|
RU2708140C1 |
| MYOCARDIAL INFARCTION TREATMENT USING TGF-BETA ANTAGONISTS | 2011 |
|
RU2637088C2 |
| ANTAGONIST ANTI-IL-7 RECEPTOR ANTIBODIES AND METHODS | 2011 |
|
RU2533809C9 |
| HUMANISED ANTIBODIES TO Toll-LIKE RECEPTORS 2 AND THEIR APPLICATIONS | 2010 |
|
RU2563344C2 |
| FUSED DRUG CONSTRUCTS AND CONJUGATES | 2005 |
|
RU2428431C2 |
| ANTI-IL-1R1 BINDING MEMBERS | 2009 |
|
RU2555532C2 |
| ANTAGONISTIC ANTIBODIES AGAINST THE IL-7 RECEPTOR AND METHODS | 2014 |
|
RU2653430C2 |
| COMPOUNDS | 2007 |
|
RU2466139C2 |
| ANTI-IL-17F ANTIBODIES AND METHODS FOR USE THEREOF | 2010 |
|
RU2605318C2 |
